HomeClinical TopicsCardio-PulmonaryFDA recommends more conservative dosing guidelines for erythropoiesis-stimulating agents

FDA recommends more conservative dosing guidelines for erythropoiesis-stimulating agents

The U.S. Food and Drug Administration (FDA) is recommending more conservative dosing guidelines for erythropoiesis-stimulating agents (ESAs) when they are used to treat anemia in patients with chronic kidney disease. FDA cites increased risks of stroke and other cardiovascular events as the reason behind the change. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...